{"id":"W4379981852","doi":"10.1002/hon.3166_ot28","title":"PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R‐CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): EPCORE DLBCL‐2","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"National Institutes of Health; National Cancer Institute; Celgene; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Rituximab; Diffuse large B-cell lymphoma; Vincristine; Cytokine release syndrome; Oncology; Prednisone; CHOP; International Prognostic Index; Cyclophosphamide; Phases of clinical research; CD20; Lymphoma; Discontinuation; Gastroenterology; Clinical trial; Chemotherapy; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000682961,0.0004691513,0.001843908,0.0005331193,0.00009910667,0.00001881077,0.00042483,0.000782718,0.001374758],"category_scores_gemma":[0.001210847,0.0003482715,0.000308864,0.001422184,0.0004347367,0.00007857749,0.0002678324,0.0006354871,0.0003831469],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006317787,"about_ca_system_score_gemma":0.0005650081,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007857669,"about_ca_topic_score_gemma":0.0001438821,"domain_scores_codex":[0.9952596,0.0005277157,0.001068783,0.0008815328,0.0009383358,0.001323997],"domain_scores_gemma":[0.9952233,0.002878178,0.0003396761,0.0007742813,0.0002735113,0.0005110459],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7539799,0.1548729,0.01718689,0.0003221808,0.0002512051,0.02746606,0.0008637865,0.00000424392,0.002359759,0.0006901312,0.003720069,0.03828283],"study_design_scores_gemma":[0.9072056,0.06839499,0.003915359,0.00008765863,0.0001370027,0.0002846544,0.0005784403,0.0003154017,0.0009759687,0.0001109486,0.01759298,0.0004010334],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894937,0.0001093987,0.0000167837,0.0005352157,0.0007027545,0.002576655,0.00006167234,0.0002182886,0.006285553],"genre_scores_gemma":[0.9971738,0.00031798,0.0002728858,0.0002595634,0.0001837864,0.0003226975,0.0001882085,0.0000764133,0.001204688],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1532256,"threshold_uncertainty_score":0.9998969,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04596949735079359,"score_gpt":0.360199123689225,"score_spread":0.3142296263384314,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}